Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity

Although treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) has significantly improved clinical outcomes in patients with rheumatoid arthritis (RA), many patients do not have access to these treatments. As cost-effective alternatives to their reference products (RPs), biosimilar...

Descripción completa

Detalles Bibliográficos
Autores principales: Huizinga, Tom W. J., Torii, Yoshifumi, Muniz, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991039/
https://www.ncbi.nlm.nih.gov/pubmed/33263165
http://dx.doi.org/10.1007/s40744-020-00259-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991039/
https://www.ncbi.nlm.nih.gov/pubmed/33263165
http://dx.doi.org/10.1007/s40744-020-00259-8

Ejemplares similares